BioSpace News Archive

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, provided a corporate update, and reported financial results for the three months ended March 31, 2021.

Applied Genetic Technologies Corporation announced that it plans to release 12-month data for Groups 5 and 6 evaluating durability of effect and continued safety at higher doses and 24-month data evaluating durability from a subset of Group 4 patients for its Phase 1/2 clinical trial in patients with X-linked Retinitis Pigmentosa on Thursday, May 6, 2021.

Newly released PK/PD data from prior study in PGHD support endogenous LUM-201 MOA and use of Predictive Enrichment Markers (PEMs) to identify patients likely to respond to LUM-201

ATTACK Phase 3 topline data readout remains on track for second half of 2021

Conformis, Inc., an orthopedic medical device company that features personalized knee and hip replacement products, announced financial results for the first quarter ended March 31, 2021.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, reported financial results for the first quarter ended March 31, 2021.

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the quarter ended March 31, 2021.

Graybug Vision, Inc., a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, announced it will host a conference call and webcast to discuss the full-data analysis of the 12-month treatment phase of its Phase 2b ALTISSIMO trial on Wednesday, May 12, 2021 at 8 a.m. Eastern time.

Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced the Company has received guidance from the U.S. Food and Drug Administration on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome.

10x Genomics, Inc. reported financial results for the first quarter ended March 31, 2021.